Showing 3811-3820 of 8681 results for "".
- Study Shows Poor Cardiovascular–Kidney–Metabolic Health Raises Risk of PsOhttps://practicaldermatology.com/news/poor-cardiovascularkidneymetabolic-health-raises-risk-of-pso/2475773/Adults with poor cardiovascular–kidney–metabolic (CKM) health face significantly higher risks of developing psoriasis and reduced life expectancy if diagnosed, new research reveals. The analysis of data from a large UK Bioba
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEO Pharma to Partner with Boehringer Ingelheim, Commercialize SPEVIGO® for GPPhttps://practicaldermatology.com/news/leo-pharma-to-partner-with-boehringer-ingelheim-commercialize-spevigo-for-gpp/2475663/LEO Pharma and Boehringer Ingelheim have entered into an exclusive global license and transfer agreement for the development and commercialization of the interleukin-36 (IL-36) receptor inhibitor SPEVIGO® (spesolimab), according to a news release.
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Upcoming Skin Cancer Champions Webinar Addresses Impact of AIhttps://practicaldermatology.com/news/Upcoming-Skin-Cancer-Champions-Webinar-Addresses-Impact-AI/2475627/Veronica Rotemberg, MD, PhD, will host a free webinar on the future of non-melanoma skin cancer care August 5 at 1:00 PM ET, Skin Cancer Champions announced. Dr. Rotemberg, Director of Dermatology Imaging Informatics for Memorial Sloan Kettering Cancer Center, will present “The Future of S
- Anaysis: Linperlisib and Chidamide Safe, Effective in Advanced CTCLhttps://practicaldermatology.com/news/anaysis-linperlisib-and-chidamide-safe-effective-in-advanced-ctcl/2475518/An investigational combination of linperlisib and chidamide demonstrated clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), according to results from a phase 1 trial. The single-arm, n
- Analysis Concludes No Single Preclinical Model Fully Mimics Human PsOhttps://practicaldermatology.com/news/Analysis-Concludes-No-Single-Preclinical-Model-Fully-Mimics-Human-PsO/2475576/Despite extensive preclinical model development, no single system fully mimics human psoriatic disease, according to a new analysis published in Expert Opinion on Drug Discovery. Researchers on the study emphasized the importance of preclinical models that can reproduce disease-re
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he
- ZORYVE Cream 0.15% Gets AAD Endorsement for Atopic Dermatitishttps://practicaldermatology.com/news/zoryve-cream-015-gets-aad-endorsement-for-atopic-dermatitis/2475411/The American Academy of Dermatology (AAD) has issued a strong recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adult patients with mild to moderate atopic dermatitis (AD), according to updated guidelines released June 26.